These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 15027118)

  • 1. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases.
    Candeil L; Gourdier I; Peyron D; Vezzio N; Copois V; Bibeau F; Orsetti B; Scheffer GL; Ychou M; Khan QA; Pommier Y; Pau B; Martineau P; Del Rio M
    Int J Cancer; 2004 May; 109(6):848-54. PubMed ID: 15027118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance.
    Westover D; Ling X; Lam H; Welch J; Jin C; Gongora C; Del Rio M; Wani M; Li F
    Mol Cancer; 2015 Apr; 14():92. PubMed ID: 25928015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia.
    To KK; Poon DC; Wei Y; Wang F; Lin G; Fu LW
    Biochem Pharmacol; 2015 Sep; 97(1):27-37. PubMed ID: 26206183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.
    Bram EE; Ifergan I; Grimberg M; Lemke K; Skladanowski A; Assaraf YG
    Biochem Pharmacol; 2007 Jun; 74(1):41-53. PubMed ID: 17481587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered expression of cell proliferation-related and interferon-stimulated genes in colon cancer cells resistant to SN38.
    Gongora C; Candeil L; Vezzio N; Copois V; Denis V; Breil C; Molina F; Fraslon C; Conseiller E; Pau B; Martineau P; Del Rio M
    Cancer Biol Ther; 2008 Jun; 7(6):822-32. PubMed ID: 18340113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A template model for studying anticancer drug efflux transporter inhibitors in vitro.
    Sostelly A; Payen L; Guitton J; Di Pietro A; Falson P; Honorat M; Valdameri G; Geze A; Boumendjel A; Freyer G; Tod M
    Fundam Clin Pharmacol; 2013 Oct; 27(5):544-56. PubMed ID: 22882086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptional targeting of human liver carboxylesterase (hCE1m6) and simultaneous expression of anti-BCRP shRNA enhances sensitivity of breast cancer cells to CPT-11.
    Mishra MN; Vangara KK; Palakurthi S
    Anticancer Res; 2014 Nov; 34(11):6345-51. PubMed ID: 25368234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular changes to HeLa cells on continuous exposure to SN-38, an active metabolite of irinotecan hydrochloride.
    Takara K; Kitada N; Yoshikawa E; Yamamoto K; Horibe S; Sakaeda T; Nishiguchi K; Ohnishi N; Yokoyama T
    Cancer Lett; 2009 Jun; 278(1):88-96. PubMed ID: 19201079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and functional analyses of breast cancer resistance protein in lung cancer.
    Kawabata S; Oka M; Soda H; Shiozawa K; Nakatomi K; Tsurutani J; Nakamura Y; Doi S; Kitazaki T; Sugahara K; Yamada Y; Kamihira S; Kohno S
    Clin Cancer Res; 2003 Aug; 9(8):3052-7. PubMed ID: 12912956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines.
    Jandu H; Aluzaite K; Fogh L; Thrane SW; Noer JB; Proszek J; Do KN; Hansen SN; Damsgaard B; Nielsen SL; Stougaard M; Knudsen BR; Moreira J; Hamerlik P; Gajjar M; Smid M; Martens J; Foekens J; Pommier Y; Brünner N; Schrohl AS; Stenvang J
    BMC Cancer; 2016 Jan; 16():34. PubMed ID: 26801902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltransferase.
    Ji N; Yuan J; Liu J; Tian S
    Acta Biochim Biophys Sin (Shanghai); 2010 Dec; 42(12):854-62. PubMed ID: 21106767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer.
    To KK; Leung WW; Ng SS
    Exp Cell Res; 2015 Nov; 338(2):222-31. PubMed ID: 26386386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative evaluation of the combination between cytotoxic drug and efflux transporter inhibitors based on a tumour growth inhibition model.
    Sostelly A; Payen L; Guitton J; Di Pietro A; Falson P; Honorat M; Boumendjel A; Gèze A; Freyer G; Tod M
    Fundam Clin Pharmacol; 2014 Apr; 28(2):161-9. PubMed ID: 23384250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
    Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
    Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
    Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
    Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
    Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Correlation of chemosensitivity tested using histoculture drug response assay to expression of multidrug resistance genes and proteins in colorectal cancer tissues].
    Yuan SQ; Zhou ZW; Liang YJ; Fu LW; Chen G; Qiu HB; Zhang LY
    Ai Zheng; 2009 Sep; 28(9):932-8. PubMed ID: 19728910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
    Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
    Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical determinants of response to irinotecan-based therapy derived from cell line models.
    Allen WL; Coyle VM; Jithesh PV; Proutski I; Stevenson L; Fenning C; Longley DB; Wilson RH; Gordon M; Lenz HJ; Johnston PG
    Clin Cancer Res; 2008 Oct; 14(20):6647-55. PubMed ID: 18927307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells.
    Yoshikawa M; Ikegami Y; Hayasaka S; Ishii K; Ito A; Sano K; Suzuki T; Togawa T; Yoshida H; Soda H; Oka M; Kohno S; Sawada S; Ishikawa T; Tanabe S
    Int J Cancer; 2004 Jul; 110(6):921-7. PubMed ID: 15170677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.